Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer

Background Immune checkpoint inhibitors (ICIs) improve survival outcomes in metastatic melanoma and non-small cell lung cancer (NSCLC). Preclinical evidence suggests that overexpression of cyclo-oxygenase-2 (COX2) in tumors facilitates immune evasion through prostaglandin E2 production and that COX...

Full description

Bibliographic Details
Main Authors: Jyoti Malhotra, Janice M Mehnert, Ann W Silk, Roman Groisberg, Shang-Jui Wang, Karishma Khullar, Sinae Kim, Nikhil Yegya-Raman, Samuel H Crayton, John L Nosher, Michael A Gentile, Salma K Jabbour
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000889.full

Internet

https://jitc.bmj.com/content/8/2/e000889.full

Similar Items